Illumina, Inc. (4ILMN.TI)
| Previous close | 95.41 |
| Open | 95.88 |
| Bid | 95.00 x N/A |
| Ask | 101.00 x N/A |
| Day's range | 95.88 - 95.88 |
| 52-week range | 86.26 - 199.48 |
| Volume | |
| Avg. volume | 8 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireIllumina appoints Everett Cunningham Chief Commercial Officer
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment of Everett Cunningham as Chief Commercial Officer (CCO), effective June 10.
PR NewswireIllumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of its latest research being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31–June 4 in Chicago. Highlights include data from several studies in partnership with Labcorp, a global leader of innovative and comprehensive laboratory services; research with Sarah Cannon Research Institute (SCRI) demonstrating further evidence to support the use of com
PR NewswireIllumina releases 2023 Corporate Social Responsibility Report
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its fifth annual Corporate Social Responsibility (CSR) Report. The report highlights the company's ongoing commitments and progress made in 2023 toward advancing human health by serving as a champion for patients, communities, employees, and the planet.
